Skip Over Navigation Links

Bridging Interventional Development Gaps

  A technician in an NCATS chemistry laboratory advancing a chemical probe through analog synthesis.

Bridging Interventional Development Gaps (BrIDGs), previously the NIH Rapid Access to Intervention Development (RAID) program, was launched under its new name in October 2011. As part of the NCATS Division of Pre-Clinical Innovation, BrIDGs makes available, on a competitive basis, certain critical resources needed for the development of new therapeutic agents. Investigators do not receive grant funds through this program. Instead, successful applicants receive access to NIH contractors who conduct preclinical studies at no cost to the investigator. In general, synthesis, formulation, pharmacokinetic and toxicology services in support of investigator-held Investigational New Drug (IND) applications to the Food and Drug Administration are available.

The next receipt date for applications to the BrIDGs program will occur in early 2013. Download the draft application instructions.

Contract costs are supported by the NIH Common Fund and collaborating NIH Institutes and Centers. Access to contracts is based upon a peer-reviewed application process. The number of awards made will depend on the number of applications received, their scientific merit, and the availability of NIH funds.

BrIDGs is not a complete drug development program or an unconditional commitment to develop a particular compound for the clinic. In some cases the program supports one or two key steps for preclinical development, while in other cases it assists with most of the development tasks needed to file an IND. The services provided by the program depend upon the stage of a given project and need for additional data.

Once a project is approved, NIH staff work with principal investigators to develop a plan for the conduct of proposed studies. Contractors perform tasks approved by BrIDGs under the direction of NIH staff. Development proceeds sequentially in most cases and the start of one segment of the project (e.g., toxicology) may depend on satisfactory completion of preceding segments (e.g., formulation). Insurmountable difficulties in one segment may force the discontinuation of an entire project.

To date, research data and material generated by BrIDGs have been involved in 12 successful INDs.

Eligibility

BrIDGs supports projects proposed by academic institutions, not-for-profit organizations, and SBIR-eligible businesses. The criteria for SBIR-eligibility can be found here. Foreign academic and non-profit institutions may also apply. NIH intramural divisions are ineligible at this time.

Potential therapies for any disease or disorder may be submitted to BrIDGs. All proposed therapeutic agents should have demonstrated pharmacological activity in an appropriate in vivo disease model before applying.